Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters

Masataka Karube, Naoyoshi Yamamoto, Yoshiyuki Shioyama, Junichi Saito, Akira Matsunobu, Tamaki Okimoto, Tatsuya Ohno, Hiroshi Tsuji, Takashi Nakano, Tadashi Kamada

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Carbon-ion radiation therapy (CIRT) for advanced non-small-cell lung cancer (NSCLC) has not been well studied to date. This paper aimed to analyze a retrospective multicenter survey for detecting problems with the use of CIRT for Stage II and III NSCLC (7th UICC TNM Staging System). Inclusion was restricted to patients with Stage II and III NSCLC who received CIRT from November 2003 to December 2014. We gathered the data from three CIRT operating centers on July 2015. Patients with radiotherapy history, patients with cancers other than lung cancer, and those receiving palliative therapies were excluded. The patient characteristics, prescribed dose/fraction, survival rates, and adverse effects were analyzed. The total number of patients was 64 (male: 49, female: 15). Of these, 53 patients were medically inoperable. The median age was 76 years (range 46-91), and the median follow-up period was 18.5 months (range 3.2-121.5). The clinical staging consisted of 10 Stage IIA, 30 Stage IIB, 23 Stage IIIA and 1 Stage IIIB. The median prescribed dose was 72.0 Gy (RBE) (range 52.8-72.0) in 16 fractions (range 4-16). The 2-year overall survival, progression-free survival, and local control rates were 62.2% [confidence interval (CI): 47.5-76.9], 42.3% (CI: 28.8-55.8) and 81.8% (CI: 69.9-94.0), respectively. There were no higher than Grade 2 adverse effects observed. CIRT for inoperable Stage II and III NSCLC could be implemented without severe adverse effects, but the clinical staging (including lymph node status) was inhomogeneous. In addition, the prescribed dose and fractionation were not standardized. Further data accumulation and a multiple centers prospective trial for evaluating clinical stage-based results are required.

Original languageEnglish
Pages (from-to)761-764
Number of pages4
JournalJournal of radiation research
Volume58
Issue number5
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Heavy Ion Radiotherapy
Non-Small Cell Lung Carcinoma
lungs
radiation therapy
cancer
carbon
confidence
ions
Confidence Intervals
intervals
dosage
Lung Neoplasms
Dose Fractionation
lymphatic system
Neoplasm Staging
Palliative Care
progressions
fractionation
Disease-Free Survival
grade

All Science Journal Classification (ASJC) codes

  • Radiation
  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis

Cite this

Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters. / Karube, Masataka; Yamamoto, Naoyoshi; Shioyama, Yoshiyuki; Saito, Junichi; Matsunobu, Akira; Okimoto, Tamaki; Ohno, Tatsuya; Tsuji, Hiroshi; Nakano, Takashi; Kamada, Tadashi.

In: Journal of radiation research, Vol. 58, No. 5, 01.09.2017, p. 761-764.

Research output: Contribution to journalReview article

Karube, M, Yamamoto, N, Shioyama, Y, Saito, J, Matsunobu, A, Okimoto, T, Ohno, T, Tsuji, H, Nakano, T & Kamada, T 2017, 'Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters', Journal of radiation research, vol. 58, no. 5, pp. 761-764. https://doi.org/10.1093/jrr/rrx037
Karube, Masataka ; Yamamoto, Naoyoshi ; Shioyama, Yoshiyuki ; Saito, Junichi ; Matsunobu, Akira ; Okimoto, Tamaki ; Ohno, Tatsuya ; Tsuji, Hiroshi ; Nakano, Takashi ; Kamada, Tadashi. / Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters. In: Journal of radiation research. 2017 ; Vol. 58, No. 5. pp. 761-764.
@article{62ad2d603ace4b7eb08ddf445b357b76,
title = "Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters",
abstract = "Carbon-ion radiation therapy (CIRT) for advanced non-small-cell lung cancer (NSCLC) has not been well studied to date. This paper aimed to analyze a retrospective multicenter survey for detecting problems with the use of CIRT for Stage II and III NSCLC (7th UICC TNM Staging System). Inclusion was restricted to patients with Stage II and III NSCLC who received CIRT from November 2003 to December 2014. We gathered the data from three CIRT operating centers on July 2015. Patients with radiotherapy history, patients with cancers other than lung cancer, and those receiving palliative therapies were excluded. The patient characteristics, prescribed dose/fraction, survival rates, and adverse effects were analyzed. The total number of patients was 64 (male: 49, female: 15). Of these, 53 patients were medically inoperable. The median age was 76 years (range 46-91), and the median follow-up period was 18.5 months (range 3.2-121.5). The clinical staging consisted of 10 Stage IIA, 30 Stage IIB, 23 Stage IIIA and 1 Stage IIIB. The median prescribed dose was 72.0 Gy (RBE) (range 52.8-72.0) in 16 fractions (range 4-16). The 2-year overall survival, progression-free survival, and local control rates were 62.2{\%} [confidence interval (CI): 47.5-76.9], 42.3{\%} (CI: 28.8-55.8) and 81.8{\%} (CI: 69.9-94.0), respectively. There were no higher than Grade 2 adverse effects observed. CIRT for inoperable Stage II and III NSCLC could be implemented without severe adverse effects, but the clinical staging (including lymph node status) was inhomogeneous. In addition, the prescribed dose and fractionation were not standardized. Further data accumulation and a multiple centers prospective trial for evaluating clinical stage-based results are required.",
author = "Masataka Karube and Naoyoshi Yamamoto and Yoshiyuki Shioyama and Junichi Saito and Akira Matsunobu and Tamaki Okimoto and Tatsuya Ohno and Hiroshi Tsuji and Takashi Nakano and Tadashi Kamada",
year = "2017",
month = "9",
day = "1",
doi = "10.1093/jrr/rrx037",
language = "English",
volume = "58",
pages = "761--764",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "5",

}

TY - JOUR

T1 - Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters

AU - Karube, Masataka

AU - Yamamoto, Naoyoshi

AU - Shioyama, Yoshiyuki

AU - Saito, Junichi

AU - Matsunobu, Akira

AU - Okimoto, Tamaki

AU - Ohno, Tatsuya

AU - Tsuji, Hiroshi

AU - Nakano, Takashi

AU - Kamada, Tadashi

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Carbon-ion radiation therapy (CIRT) for advanced non-small-cell lung cancer (NSCLC) has not been well studied to date. This paper aimed to analyze a retrospective multicenter survey for detecting problems with the use of CIRT for Stage II and III NSCLC (7th UICC TNM Staging System). Inclusion was restricted to patients with Stage II and III NSCLC who received CIRT from November 2003 to December 2014. We gathered the data from three CIRT operating centers on July 2015. Patients with radiotherapy history, patients with cancers other than lung cancer, and those receiving palliative therapies were excluded. The patient characteristics, prescribed dose/fraction, survival rates, and adverse effects were analyzed. The total number of patients was 64 (male: 49, female: 15). Of these, 53 patients were medically inoperable. The median age was 76 years (range 46-91), and the median follow-up period was 18.5 months (range 3.2-121.5). The clinical staging consisted of 10 Stage IIA, 30 Stage IIB, 23 Stage IIIA and 1 Stage IIIB. The median prescribed dose was 72.0 Gy (RBE) (range 52.8-72.0) in 16 fractions (range 4-16). The 2-year overall survival, progression-free survival, and local control rates were 62.2% [confidence interval (CI): 47.5-76.9], 42.3% (CI: 28.8-55.8) and 81.8% (CI: 69.9-94.0), respectively. There were no higher than Grade 2 adverse effects observed. CIRT for inoperable Stage II and III NSCLC could be implemented without severe adverse effects, but the clinical staging (including lymph node status) was inhomogeneous. In addition, the prescribed dose and fractionation were not standardized. Further data accumulation and a multiple centers prospective trial for evaluating clinical stage-based results are required.

AB - Carbon-ion radiation therapy (CIRT) for advanced non-small-cell lung cancer (NSCLC) has not been well studied to date. This paper aimed to analyze a retrospective multicenter survey for detecting problems with the use of CIRT for Stage II and III NSCLC (7th UICC TNM Staging System). Inclusion was restricted to patients with Stage II and III NSCLC who received CIRT from November 2003 to December 2014. We gathered the data from three CIRT operating centers on July 2015. Patients with radiotherapy history, patients with cancers other than lung cancer, and those receiving palliative therapies were excluded. The patient characteristics, prescribed dose/fraction, survival rates, and adverse effects were analyzed. The total number of patients was 64 (male: 49, female: 15). Of these, 53 patients were medically inoperable. The median age was 76 years (range 46-91), and the median follow-up period was 18.5 months (range 3.2-121.5). The clinical staging consisted of 10 Stage IIA, 30 Stage IIB, 23 Stage IIIA and 1 Stage IIIB. The median prescribed dose was 72.0 Gy (RBE) (range 52.8-72.0) in 16 fractions (range 4-16). The 2-year overall survival, progression-free survival, and local control rates were 62.2% [confidence interval (CI): 47.5-76.9], 42.3% (CI: 28.8-55.8) and 81.8% (CI: 69.9-94.0), respectively. There were no higher than Grade 2 adverse effects observed. CIRT for inoperable Stage II and III NSCLC could be implemented without severe adverse effects, but the clinical staging (including lymph node status) was inhomogeneous. In addition, the prescribed dose and fractionation were not standardized. Further data accumulation and a multiple centers prospective trial for evaluating clinical stage-based results are required.

UR - http://www.scopus.com/inward/record.url?scp=85032447134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032447134&partnerID=8YFLogxK

U2 - 10.1093/jrr/rrx037

DO - 10.1093/jrr/rrx037

M3 - Review article

C2 - 28992088

AN - SCOPUS:85032447134

VL - 58

SP - 761

EP - 764

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 5

ER -